Загрузка...
PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration
PEGylated arginine deiminase (ADI-PEG 20) is being investigated in clinical studies in arginine auxotrophic cancers and is well-tolerated. The anti-tumor properties of ADI-PEG 20 have been extensively investigated - ADI-PEG 20 inhibits the growth of auxotrophic cancers in vitro and in vivo - however...
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5601705/ https://ncbi.nlm.nih.gov/pubmed/28938609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19564 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|